Trendspotting 2023: On the Pulse of Global Life Sciences
Environmental, Social, and Governance (ESG) Programs will be Subject to Increased Scrutiny
January 2023
Key Takeaways
- ESG programs are under enhanced scrutiny as investors and regulators probe questions such as diversity in clinical trials, access to healthcare and drug pricing, and the environmental impact of drugs and their packaging.
- The U.S. Securities and Exchange Commission (SEC) has recently begun to actively use its powers to push for ESG disclosure, with two new proposed rules.
- Two EU directives will have a major impact on life sciences companies’ ESG programs.
Contacts
Capabilities
Suggested News & Insights
EU Forced Labor Regulation Moves Toward Implementation: How Companies Should PrepareJuly 7, 2026Sidley Top-Ranked in Chambers Crisis & Risk Management 2026June 25, 2026Sidley Advises on Genting Group’s Landmark US$1.25 Billion Perpetual Securities Issuance and Concurrent US$1.5 Billion Tender OfferMay 20, 2026Global ESG and Sustainability Update: Reporting & Due Diligence Developments and Compliance StrategiesTuesday, May 19, 2026Industrial Accelerator Act: A New Framework for EU (Sustainable) Industrial GrowthApril 9, 2026Generative AI and Privilege: Practical Lessons from Two Early Decisions and What Comes NextFebruary 27, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory